Author

Sergey Polenkov

Observed name: S Polenkov

Observed institutions: Avera Health, Kidwai Memorial Institute of Oncology, St. Luke's Medical Center, Pyatigorsk Oncology Center, Janssen (Germany), Dnipro State Medical University

OpenAlex ID: A5015317835

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

2016 · Brian Leyland-Jones, Igor Bondarenko, et al. · Journal of Clinical Oncology · 74

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

2025 · Michael Wang, Michael Wang, et al. · Journal of Clinical Oncology · 67

Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

2015 · Brian Leyland-Jones, Igor Bondarenko, et al. · Cancer Research · 4

A safety and efficacy study of bleomycin sulfate and electroporation in patients with metastatic or locally recurrent breast cancer

2007 · V Paramanov, O Tyurin, et al. · Breast Cancer Research · 4

Abstract P1-14-01: Final analysis of overall survival (OS) for the epoetin alfa (EPO) phase 3 study, EPO-ANE-3010, of EPO plus standard supportive care (SOC) versus SOC in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

2018 · B Leyland-Jones, I Bondarenko, et al. · Cancer Research · 2

Works count: 5

Citation count: 150

H-index: 4

I10-index: 2